LabMedica: New Alzheimer’s Detecting Blood Tests Perform across Broad Range of Races and Ethnicities

By LabMedica International staff writersPosted on 29 Feb 2024      Alzheimer’s disease, which traditionally requires costly scans or invasive spinal taps for diagnosis, is now closer to being more easily identified through innovative blood tests. This advancement is particularly crucial with the recent approval of disease-modifying treatments for Alzheimer’s. Now, the results of a study […]

Read more »

Precision Medicine Online: Blood-Based Tests for Alzheimer’s Biomarkers Tau, Beta-Amyloid Prove Promising in Bio-Hermes Study

Feb 28, 2024 | Jessica Kim Cohen NEW YORK – Results from blood-based biomarker tests correlated with the presence of beta-amyloid detected using established Alzheimer’s disease diagnostics, according to a study published Wednesday. PET scans and cerebrospinal fluid (CSF) analyses are highly accurate and established methods of identifying elevated levels of beta-amyloid, a hallmark of Alzheimer’s. However, these […]

Read more »

Promising Pathways to Simplified Alzheimer’s Diagnosis Unveiled in Groundbreaking Study

The results of the Bio-Hermes study appear in Alzheimer’s & Dementia showing how new Alzheimer’s detecting blood tests perform across a broad range of races and ethnicities for the first time. Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study in over […]

Read more »

Atlanta News First: Metro Atlanta veteran wins national award for volunteering in Alzheimer’s research

By Hope Dean, Published: Feb. 21, 2024 at 3:31 PM EST ATLANTA, Ga. (Atlanta News First) – A veteran from Ellenwood is being recognized by a nonprofit foundation for helping advance research on Alzheimer’s disease. Rod Barber won the National Citizen Scientist Catalyst Award, the Global Alzheimer’s Platform Foundation announced on Monday. He has volunteered at CenExel iResearch in […]

Read more »

New Alzheimer’s drugs bring hope. But not equally for all patients.

The medications have not been widely tested in Black people with the disease,underscoring stark — and persistent — disparities By Laurie McGinley, January 29, 2024 at 6:00 a.m. EST ABINGTON, Pa. — Wrapped in a purple blanket, Robert Williford settles into a quiet corner of abustling neurology clinic, an IV line delivering a colorless liquid […]

Read more »

New blood test could screen for Alzheimer’s before onset of symptoms

By Evyn Moon, PublishedJanuary 23, 2024 9:42AM, Health, FOX 13 News TAMPA, Fla. – A blood test could soon be used to identify a type of protein that is linked to Alzheimer’s disease before symptoms arise with 97% accuracy, a new study shows.  The study involves testing blood for biomarkers that could build up in the brain. The testing could […]

Read more »

Alzheimer’s group amps public pressure with ad campaign as Medicare decision looms

A new seven-figure ad campaign takes aim – again – at Medicare’s pending coverage decision on Alzheimer’s disease anti-amyloid drugs. UsAgainstAlzheimer’s launched the $1 million-plus national effort Sunday, including a TV ad that ran across the the day’s morning talk news shows. The group is the latest to push back on the Centers for Medicare […]

Read more »

Investors Meet Opportunity at Inaugural Global Alzheimer’s Platform Foundation Innovation Summit

At a pivotal time in Alzheimer’s research, the GAP Foundation and the Alzheimer’s Drug Discovery Foundation will connect funders with leading innovators Updated on March 26, 2020: The Global Alzheimer’s Platform Foundation (GAP) has announced it is postponing the GAP Innovation Summit that was to be held on May 5, 2020 with our partner, the […]

Read more »

A Meeting of the Minds

For the first time in 15 years, there are new Alzheimer’s drug treatments on the horizon that are expected to seek regulatory approval by the FDA and leading experts are increasely optimistic that a major breakthrough in Alzheimer’s research will occur within the next five years. We are at a moment of peak opportunity – […]

Read more »
To top